SF3B1 and intrahepatic cholangiocarcinoma: In contrast to the WHO 2022, the International Consensus Classification (ICC) requires an SF3B1 variant allelic frequency (VAF) ≥ 10% in the absence of certain cytogenetic abnormalities, RUNX1 and multi-hit TP53 (Supplementary Table S1) [12].